Explosive Growth In Scientific Discovery.
Shrinking support from traditional sources of funding. Exciting investment opportunities for family offices and ultra high-net worth individuals. Locust Walk connects great companies and visionary investors.
Recent trends in biopharma investment have yielded new opportunities for families and individuals who have capacity and interest in investing in early-stage biopharma ventures. Capital invested in private biopharma companies has increased over the past few years. At the same time, the number of venture capitalists actively investing in this space has decreased significantly. Some have shifted their focus to launching their own companies in-house. Many have turned to later-stage investment in advanced, clinical stage, pre-IPO companies.
Family offices – firms established for the strategic management of the wealth and affairs of one or more affluent families, typically with $100 million to greater than $1 billion in assets (exceeding the asset levels of typical angel investors) – often operate on the dual imperatives of profit motive and social value.
Early-stage biopharma entrepreneurs who seek capital are connecting with non-traditional investors, such as family offices.
Locust Walk delivers the expertise and comprehensive services that family offices need to achieve both positive financial returns and meaningful social impact.
Our seasoned advisors help high-net-worth individuals and families successfully navigate biopharma’s uniquely challenging landscape – providing access to quality deal flow, due diligence, risk and opportunity assessment, and post-funding investment management.
- Portfolio review and assessment
- Business case development
- Development of strategic options
- Transaction lead and execution
- Improved returns
- Unique and relevant deal flow
- Comprehensive due diligence
- Syndicate development
- Deal structuring and negotiations
- Ongoing oversight
Locust Walk Capital
- Unique deal flow
- First look
- Compatibility with family mission
- Limited partner participation
- Capital-efficient infrastructure